Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Teva
Colorcon
Healthtrust
Boehringer Ingelheim
UBS

Generated: September 22, 2019

DrugPatentWatch Database Preview

Patent: 8,840,887

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,840,887
Title:Antibodies
Abstract: The present invention relates to the use of VEGF antagonists and a novel anti-.alpha.5.beta.1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-.alpha.5.beta.1 antibodies and methods of making and using them.
Inventor(s): Liang; Wei-Ching (Foster City, CA), Plowman; Gregory D. (San Carlos, CA), Wu; Yan (Foster City, CA), Ye; Weilan (Foster City, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:13/112,839
Patent Claims:see list of patent claims

Details for Patent 8,840,887

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Try a Free Trial Genentech, Inc. (South San Francisco, CA) 2027-09-26 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Try a Free Trial Genentech, Inc. (South San Francisco, CA) 2027-09-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Johnson and Johnson
Citi
Argus Health
Baxter
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.